CardioCell LLC   Report issue

For profit Phase 2
Founded: San Diego CA United States (2013)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2013
NCT01770613
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

allogeneic hematopoietic stem cells (Hemacord) (1 trial)

stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 2)

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2